Business Wire

ANT-GROUP

31.5.2022 08:34:04 CEST | Business Wire | Press release

Share
Ant Group Appointed by Elevandi as Advisory Committee Member

Ant Group has been appointed as a member on the advisory committee of Elevandi, a company set up by the Monetary Authority of Singapore (MAS) with a mission to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy.

The advisory committee comprises senior leaders from eight organizations ranging from established financial institutions to Tech/FinTech players. Mr. Chen Leiming, Senior Vice President, who is responsible for Ant Group’s international public policy and government affairs, serves as the representative of Ant Group. Mr. Chen also oversees the legal, compliance, AML and privacy functions of Ant Group’s international businesses.

As an advisory committee member, Mr. Chen Leiming will represent Ant Group and involve in providing strategic guidance on:

  1. galvanising global conversations to shape FinTech industry agendas worldwide;
  2. identifying key structural trends and issues shaping the future of financial services; and
  3. fostering an open dialogue between policymakers and FinTech players on Fintech risks and opportunities.

Speaking on the appointment of Ant Group as an advisory committee member, Mr. Sopnendu Mohanty, Chairman of Elevandi’s Board of Directors and Chief FinTech Officer of MAS, said: “Elevandi's mission is to bring together the public and private sector to adopt technology and build the future of finance that is inclusive, impactful and sustainable. We welcome organisations that have shown passion and dedication in harnessing FinTech for the growth and development of the new digital economy to participate as advisory committee members.”

Mr. Chen Leiming, Senior Vice President, Ant Group, said: “It is a great honour to represent Ant Group and contribute to the mission of Elevandi which we share and resonate deeply. At Ant Group, we are committed to leveraging technology and knowledge to provide inclusive services to those unserved and underserved, and contribute to the society through initiatives such as Ant Forest to promote low carbon lifestyle, and 10x1000 Tech for Inclusion to bridge the global digital skills gap."

"We look forward to joining the fellow members of the advisory committee in furthering Elevandi’s efforts on cultivating a more inclusive, green, and sustainable fintech landscape for the future," Mr. Chen said.

As part of Ant Group’s participation in Elevandi, Mr. Douglas Feagin, Senior Vice President for Global Strategic Partnerships and Investments at Ant Group will attend Elevandi’s inaugural Point Zero Forum in Zurich as a speaker. Point Zero Forum is an invite-only, in-person gathering to frame new ideas in Web 3.0 and sustainable finance; develop new regulatory frameworks; and provide access to investment capital.

For more information on Elevandi and the full list of advisory committee members, please visit https://www.elevandi.io/media/company-set-up-by-mas-to-advance-fintech-announces-advisory-committee .

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

About Elevandi

Elevandi is set up by the Monetary Authority of Singapore (MAS) to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy. We work closely with governments, founders, investors, and corporate leaders to drive collaboration, education, and new sources of value at the industry and national levels. Our initiatives have convened over 300,000 people since 2016 to drive the growth of FinTech through events, closed-door roundtables, investor programmes, educational initiatives, and research. ​​

We have built a coordinated set of consequential products that drive activity at the industry, national, regional and global level, which include:

  • Singapore FinTech Festival (2-4 Nov 2022) , our annual flagship event for the global FinTech community.
  • Point Zero Forum (21-23 June 2022), our invite only collaboration with the Switzerland government to convene leaders, investors and founders in Zurich.
  • Elevandi Connects (7 July 2022), our programme and initiative to bring together early stage start-ups with leading investors and corporates to maximise commercial success in forging investment deals, co-innovation opportunities, and business partnerships.
  • World FinTech Festival (July-Nov 2022), our partnerships with the public and private sectors in markets around the world.
  • Green Shoots Series, our monthly event meetup which serves as a platform for public and private sector announcements and to discuss critical issues and opportunities in FinTech and the digital economy.
  • Education initiatives, our certificates and mentoring programmes to upskill and reskill the global FinTech community in collaboration with Oxygen by APIX, academic and industry partners.
  • Elevandi Forums, our purpose-driven roundtables aimed at bringing the public and private sectors together to advance developments and issues within the FinTech industry.
  • Elevandi FinTech Insider Report , our reports on digital advancements for the global FinTech industry which synthesise knowledge from our activities with the public and private sectors.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye